Doxofylline ( INN), (also known as doxophylline) is a xanthine derivative drug used in the treatment of asthma. [1 ]
antitussive and bronchodilator effects, and acts as a [2 ] phosphodiesterase inhibitor. [3 ]
In animal and human studies, it has shown similar efficacy to
theophylline but with significantly fewer side effects. [4 ]
Unlike other xanthines, doxofylline lacks any significant
affinity for adenosine receptors and does not produce stimulant effects. This suggests that its antiasthmatic effects are mediated by another mechanism, perhaps its actions on phosphodiesterase. [1 ]
References [ edit ]
^ a b Cirillo R, Barone D, Franzone JS (1988). "Doxofylline, an antiasthmatic drug lacking affinity for adenosine receptors". Arch Int Pharmacodyn Ther 295: 221–37. PMID 3245738.
^ Poggi R, Brandolese R, Bernasconi M, Manzin E, Rossi A (October 1989). "Doxofylline and respiratory mechanics. Short-term effects in mechanically ventilated patients with airflow obstruction and respiratory failure". Chest 96 (4): 772–8. doi: 10.1378/chest.96.4.772. PMID 2791671.
^ Dini FL, Cogo R (2001). "Doxofylline: a new generation xanthine bronchodilator devoid of major cardiovascular adverse effects". Curr Med Res Opin 16 (4): 258–68. doi: 10.1185/030079901750120196. PMID 11268710.
^ Sankar J, Lodha R, Kabra SK (March 2008). "Doxofylline: The next generation methylxanthine". Indian J Pediatr 75 (3): 251–4. doi: 10.1007/s12098-008-0054-1. PMID 18376093.
Dali Shukla, Subhashis Chakraborty, Sanjay Singh & Brahmeshwar Mishra. Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy. 2009; 10(14): 2343-2356, DOI 10.1517/14656560903200667,